Boehringer Ingelheim received CHMP backing for JASCAYD (nerandomilast) for IPF and PPF. The CHMP recommended EU approval after Phase III FIBRONEER trials showed slowed FVC decline in IPF and PPF. The oral preferential PDE4B inhibitor is already authorized in multiple countries.
Insights / Pharma
PharmaBoehringer Ingelheim CHMP backs JASCAYD for IPF and PPF
The CHMP has recommended EU approval for Boehringer Ingelheim JASCAYD (nerandomilast) for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis after Phase III FIBRONEER trials showed slowed FVC decline.
